Previous 10 | Next 10 |
Clinical-stage biopharmaceutical companies Karuna Therapeutics (NASDAQ: KRTX) and Reata Pharmaceuticals (NASDAQ: RETA) are up more than 64% and 17% so far this year thanks to potential blockbuster drugs. Karuna's lead candidate, KarXT, has excited investors becau...
Reata Pharmaceuticals, Inc . (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that abstracts highlighting clinical data for omaveloxolone and disease education data on Friedreich...
Summary The disappointing healthcare stocks sector may convince investors to unload some names. Investors may have less confidence in Reata Pharmaceuticals, Inc. now. The stock price appears overvalued given the poor outlook for the company's treatments. Healthcare...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips On a sharply down day at the tail end of the week, Reata Pharmaceuticals (NASDAQ: RETA ) provided a dramatic counterpoint. While the benchmark S&P 500 index slipped near 2% down, RETA stock gained over 16% after r...
Reata Pharmaceuticals ( NASDAQ: RETA ) on Thursday said the U.S. FDA had informed the company that it was not planning to hold an advisory committee meeting for the review of its new drug application for its Friedreich's ataxia treatment. The company is developing an inves...
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (“FDA”) has...
Summary Stanley Druckenmiller’s 13F portfolio value decreased from $2.65B to $1.63B this quarter. Duquesne added Eli Lilly and CrowdStrike while reducing Microsoft, Freeport-McMoRan, and Teck Resources. They also dropped Amazon.com. The top three positions are at ~34% o...
The shares of clinical-stage biopharma companies Reata Pharmaceuticals ( NASDAQ: RETA ) and Ardelyx ( ARDX ) gained on Wednesday as an expert panel of the FDA is set to decide whether to recommend approval for an amyotrophic lateral sclerosis treatment developed by Amylyx Ph...
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that management will participate in investor meetings at the Citi 17 th Annual BioPharma Conference on ...
The U.S. Food and Drug Administration (FDA) extended the review period of Reata Pharmaceuticals' ( NASDAQ: RETA ) application by three months drug which seeking the approval of omaveloxolone to treat Friedreich's Ataxia. The FDA is now expected to make a decisi...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...